These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 34188004)
21. Telmisartan to prevent recurrent stroke and cardiovascular events. Yusuf S; Diener HC; Sacco RL; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; VanderMaelen C; Voigt T; Weber M; Yoon BW; N Engl J Med; 2008 Sep; 359(12):1225-37. PubMed ID: 18753639 [TBL] [Abstract][Full Text] [Related]
22. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Verma S; Poulter NR; Bhatt DL; Bain SC; Buse JB; Leiter LA; Nauck MA; Pratley RE; Zinman B; Ørsted DD; Monk Fries T; Rasmussen S; Marso SP Circulation; 2018 Dec; 138(25):2884-2894. PubMed ID: 30566004 [TBL] [Abstract][Full Text] [Related]
23. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial. Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA; Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009 [TBL] [Abstract][Full Text] [Related]
24. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Yusuf S Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907 [TBL] [Abstract][Full Text] [Related]
25. The HOPE Study (Heart Outcomes Prevention Evaluation). Sleight P J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789 [TBL] [Abstract][Full Text] [Related]
26. Angiotensin II and trials of cardiovascular outcomes. Sleight P Am J Cardiol; 2002 Jan; 89(2A):11A-16A; discussion 16A-17A. PubMed ID: 11835905 [TBL] [Abstract][Full Text] [Related]
27. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Böhm M; Schumacher H; Leong D; Mancia G; Unger T; Schmieder R; Custodis F; Diener HC; Laufs U; Lonn E; Sliwa K; Teo K; Fagard R; Redon J; Sleight P; Anderson C; O'Donnell M; Yusuf S Hypertension; 2015 Mar; 65(3):651-61. PubMed ID: 25583157 [TBL] [Abstract][Full Text] [Related]
28. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S; Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395 [TBL] [Abstract][Full Text] [Related]
29. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154 [TBL] [Abstract][Full Text] [Related]
30. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S; Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201 [TBL] [Abstract][Full Text] [Related]
31. Telmisartan, ramipril, or both in patients at high risk for vascular events. ; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520 [TBL] [Abstract][Full Text] [Related]
32. Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography. Gaggin HK; Liu Y; Lyass A; van Kimmenade RR; Motiwala SR; Kelly NP; Mallick A; Gandhi PU; Ibrahim NE; Simon ML; Bhardwaj A; Belcher AM; Harisiades JE; Massaro JM; D'Agostino RB; Januzzi JL Circulation; 2017 Jan; 135(2):116-127. PubMed ID: 27881568 [TBL] [Abstract][Full Text] [Related]
33. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Cavender MA; Scirica BM; Bonaca MP; Angiolillo DJ; Dalby AJ; Dellborg M; Morais J; Murphy SA; Ophuis TO; Tendera M; Braunwald E; Morrow DA Circulation; 2015 Mar; 131(12):1047-53. PubMed ID: 25681464 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. Gencer B; Mach F; Murphy SA; De Ferrari GM; Huber K; Lewis BS; Ferreira J; Kurtz CE; Wang H; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP JAMA Cardiol; 2020 Aug; 5(8):952-957. PubMed ID: 32432684 [TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). Redon J; Mancia G; Sleight P; Schumacher H; Gao P; Pogue J; Fagard R; Verdecchia P; Weber M; Böhm M; Williams B; Yusoff K; Teo K; Yusuf S; J Am Coll Cardiol; 2012 Jan; 59(1):74-83. PubMed ID: 22192672 [TBL] [Abstract][Full Text] [Related]
36. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Held C; Gerstein HC; Yusuf S; Zhao F; Hilbrich L; Anderson C; Sleight P; Teo K; Circulation; 2007 Mar; 115(11):1371-5. PubMed ID: 17339550 [TBL] [Abstract][Full Text] [Related]
37. Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend. Van Mieghem W; Billiouw JM; Brohet C; Dupont AG; Gazagnes MD; Heller F; Krzesinski JM; Missault L; Persu A; Piérard L; Rottiers R; Vanhooren G; Vervaet P; Herman AG Acta Clin Belg; 2010; 65(2):107-14. PubMed ID: 20491360 [TBL] [Abstract][Full Text] [Related]
38. Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. Ferreira JP; Duarte K; Pfeffer MA; McMurray JJV; Pitt B; Dickstein K; Zannad F; Rossignol P; Eur J Heart Fail; 2018 Feb; 20(2):323-331. PubMed ID: 29314455 [TBL] [Abstract][Full Text] [Related]
39. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Kjeldsen SE; Berge E; Bangalore S; Messerli FH; Mancia G; Holzhauer B; Hua TA; Zappe D; Zanchetti A; Weber MA; Julius S Blood Press; 2016; 25(2):83-92. PubMed ID: 26511535 [TBL] [Abstract][Full Text] [Related]
40. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme. Zimmermann M; Unger T Expert Opin Pharmacother; 2004 May; 5(5):1201-8. PubMed ID: 15155118 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]